The present invention relates to a β3 adrenergic receptor agonist of formula (1) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
本发明涉及一种式(1)的β3肾上腺素能受体激动剂或其药物盐;用于治疗II型糖尿病和/或肥胖症。
3-substituted oxindole beta3 agonists
申请人:Bastian Anne Jolie
公开号:US20050020617A1
公开(公告)日:2005-01-27
The present invention relates to a β3 adrenegc receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetess and/or obesity.
本发明涉及一种式(I)的β3肾上腺素受体激动剂或其药物盐;用于治疗2型糖尿病和/或肥胖症。
Beta 3 adrenergic agonists
申请人:Bastian Anne Jolie
公开号:US20050020618A1
公开(公告)日:2005-01-27
The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
本发明涉及一种公式(I)的β3肾上腺素能受体激动剂或其药用盐;适用于治疗II型糖尿病和/或肥胖症。
β3 adrenergic agonists
申请人:Eli Lilly and Company
公开号:US07241772B2
公开(公告)日:2007-07-10
The present invention relates to 2-imidazo[1,5-a]pyridine containing β3 adrenergic receptor agonists or pharmaceutical salts thereof.
本发明涉及含有β3肾上腺素能受体激动剂或其药物盐的2-咪唑[1,5-a]吡啶。
3-Substituted oxindole β3 agonists
申请人:Eli Lilly and Company
公开号:US07205407B2
公开(公告)日:2007-04-17
The present invention relates to a β3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity